Issue navigation
Volume 3, Issue 1, January-December 2021
Editorial
Call for emergency action to limit global temperature increases, restore biodiversity, and protect health: Wealthy nations must do much more, much faster
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab111, https://doi.org/10.1093/noajnl/vdab111
Basic and Translational Investigations
A brain-penetrant microtubule-targeting agent that disrupts hallmarks of glioma tumorigenesis
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdaa165, https://doi.org/10.1093/noajnl/vdaa165
Glucose transporter Glut1 controls diffuse invasion phenotype with perineuronal satellitosis in diffuse glioma microenvironment
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdaa150, https://doi.org/10.1093/noajnl/vdaa150
Glycolytic expression in lower-grade glioma reveals an epigenetic association between IDH mutation status and PDL1/2 expression
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdaa162, https://doi.org/10.1093/noajnl/vdaa162
The mutational landscape of spinal chordomas and their sensitive detection using circulating tumor DNA
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdaa173, https://doi.org/10.1093/noajnl/vdaa173
Clinical, molecular, metabolic, and immune features associated with oxidative phosphorylation in melanoma brain metastases
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdaa177, https://doi.org/10.1093/noajnl/vdaa177
Radiogenomic modeling predicts survival-associated prognostic groups in glioblastoma
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab004, https://doi.org/10.1093/noajnl/vdab004
Thrombospondin-1 mimetics are promising novel therapeutics for MYC-associated medulloblastoma
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab002, https://doi.org/10.1093/noajnl/vdab002
The glutamine antagonist prodrug JHU-083 slows malignant glioma growth and disrupts mTOR signaling
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdaa149, https://doi.org/10.1093/noajnl/vdaa149
Droplet digital PCR-based detection of circulating tumor DNA from pediatric high grade and diffuse midline glioma patients
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab013, https://doi.org/10.1093/noajnl/vdab013
Human gut microbial communities dictate efficacy of anti-PD-1 therapy in a humanized microbiome mouse model of glioma
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab023, https://doi.org/10.1093/noajnl/vdab023
FoundationOne CDx testing accurately determines whole arm 1p19q codeletion status in gliomas
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab017, https://doi.org/10.1093/noajnl/vdab017
ABCB1 inhibition provides a novel therapeutic target to block TWIST1-induced migration in medulloblastoma
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab030, https://doi.org/10.1093/noajnl/vdab030
MR1 overexpression correlates with poor clinical prognosis in glioma patients
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab034, https://doi.org/10.1093/noajnl/vdab034
Clinical utility of comprehensive genomic profiling in central nervous system tumors of children and young adults
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab037, https://doi.org/10.1093/noajnl/vdab037
Multicellular “hotspots” harbor high-grade potential in lower-grade gliomas
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab026, https://doi.org/10.1093/noajnl/vdab026
Selumetinib normalizes Ras/MAPK signaling in clinically relevant neurofibromatosis type 1 minipig tissues in vivo
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab020, https://doi.org/10.1093/noajnl/vdab020
The state of neuro-oncology during the COVID-19 pandemic: a worldwide assessment
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab035, https://doi.org/10.1093/noajnl/vdab035
Receptor-driven invasion profiles in diffuse intrinsic pontine glioma
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab039, https://doi.org/10.1093/noajnl/vdab039
Integrative molecular characterization of pediatric spinal ependymoma: the UK Children’s Cancer and Leukaemia Group study
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab043, https://doi.org/10.1093/noajnl/vdab043
NBAT1/CASC15-003/USP36 control MYCN expression and its downstream pathway genes in neuroblastoma
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab056, https://doi.org/10.1093/noajnl/vdab056
5-Aminolevulinic acid-guided resection improves the overall survival of patients with glioblastoma—a comparative cohort study of 343 patients
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab047, https://doi.org/10.1093/noajnl/vdab047
Glioma-associated microglia/macrophages augment tumorigenicity in canine astrocytoma, a naturally occurring model of human glioma
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab062, https://doi.org/10.1093/noajnl/vdab062
Irradiation of Nf1 mutant mouse models of spinal plexiform neurofibromas drives pathologic progression and decreases survival
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab063, https://doi.org/10.1093/noajnl/vdab063
Prospective prediction of clinical drug response in high-grade gliomas using an ex vivo 3D cell culture assay
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab065, https://doi.org/10.1093/noajnl/vdab065
Cystathionine-γ-lyase drives antioxidant defense in cysteine-restricted IDH1-mutant astrocytomas
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab057, https://doi.org/10.1093/noajnl/vdab057
Single-cell image analysis reveals a protective role for microglia in glioblastoma
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab031, https://doi.org/10.1093/noajnl/vdab031
Expression of cell type incongruent alpha-cardiac actin 1 subunit in medulloblastoma reveals a novel mechanism for cancer cell survival and control of migration
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab064, https://doi.org/10.1093/noajnl/vdab064
The spectrum of mitochondrial DNA (mtDNA) mutations in pediatric CNS tumors
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab074, https://doi.org/10.1093/noajnl/vdab074
The effects of palbociclib in combination with radiation in preclinical models of aggressive meningioma
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab085, https://doi.org/10.1093/noajnl/vdab085
Application of Raman spectroscopy for detection of histologically distinct areas in formalin-fixed paraffin-embedded glioblastoma
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab077, https://doi.org/10.1093/noajnl/vdab077
Distinct difference in tumor-infiltrating immune cells between Wilms’ tumor gene 1 peptide vaccine and anti-programmed cell death-1 antibody therapies
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab091, https://doi.org/10.1093/noajnl/vdab091
Preoperative imaging of glioblastoma patients using hyperpolarized 13C pyruvate: Potential role in clinical decision making
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab092, https://doi.org/10.1093/noajnl/vdab092
Radiation and adjuvant drug-loaded liposomes target glioblastoma stem cells and trigger in-situ immune response
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab076, https://doi.org/10.1093/noajnl/vdab076
Descriptive and retrospective analysis of diffuse glioma patients with symptomatic SARS-CoV2 infection during the first wave of the pandemic
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab078, https://doi.org/10.1093/noajnl/vdab078
Clinical and molecular analysis of smoothened inhibitors in Sonic Hedgehog medulloblastoma
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab097, https://doi.org/10.1093/noajnl/vdab097
Parents’ experiences of postmortem tumor donation for high-grade gliomas: benefits and suggested improvements
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab087, https://doi.org/10.1093/noajnl/vdab087
Inhibition of microglial EZH2 leads to anti-tumoral effects in pediatric diffuse midline gliomas
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab096, https://doi.org/10.1093/noajnl/vdab096
Histone deacetylase inhibitors enhance estrogen receptor beta expression and augment agonist-mediated tumor suppression in glioblastoma
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab099, https://doi.org/10.1093/noajnl/vdab099
Tumor volumes as a predictor of response to the anti-EGFR antibody drug conjugate depatuxizumab mafadotin
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab102, https://doi.org/10.1093/noajnl/vdab102
Generation, characterization, and drug sensitivities of 12 patient-derived IDH1-mutant glioma cell cultures
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab103, https://doi.org/10.1093/noajnl/vdab103
Transitioning to molecular diagnostics in pediatric high-grade glioma: experiences with the 2016 WHO classification of CNS tumors
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab113, https://doi.org/10.1093/noajnl/vdab113
Intracranially injectable multi-siRNA nanomedicine for the inhibition of glioma stem cells
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab104, https://doi.org/10.1093/noajnl/vdab104
Feasibility of magnetic resonance-guided high-intensity focused ultrasound treatment targeting distinct nodular lesions in neurofibromatosis type 1
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab116, https://doi.org/10.1093/noajnl/vdab116
A genetic mouse model with postnatal Nf1 and p53 loss recapitulates the histology and transcriptome of human malignant peripheral nerve sheath tumor
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab129, https://doi.org/10.1093/noajnl/vdab129
Raised cardiovascular disease mortality after central nervous system tumor diagnosis: analysis of 171,926 patients from UK and USA
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab136, https://doi.org/10.1093/noajnl/vdab136
Anesthesia triggers drug delivery to experimental glioma in mice by hijacking caveolar transport
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab140, https://doi.org/10.1093/noajnl/vdab140
Prognostic implications of epidermal and platelet-derived growth factor receptor alterations in 2 cohorts of IDHwt glioblastoma
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab127, https://doi.org/10.1093/noajnl/vdab127
ELTD1 as a multi-focal target for malignant gliomas: preclinical studies
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab132, https://doi.org/10.1093/noajnl/vdab132
Comparative evaluation of T-cell receptors in experimental glioma-draining lymph nodes
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab147, https://doi.org/10.1093/noajnl/vdab147
Identification of five important genes to predict glioblastoma subtypes
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab144, https://doi.org/10.1093/noajnl/vdab144
Gemcitabine radiosensitization primes irradiated malignant meningioma cells for senolytic elimination by navitoclax
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab148, https://doi.org/10.1093/noajnl/vdab148
Glioblastoma cytotoxicity conferred through dual disruption of endolysosomal homeostasis by Vacquinol-1
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab152, https://doi.org/10.1093/noajnl/vdab152
Homotopic functional connectivity disruptions in glioma patients are associated with tumor malignancy and overall survival
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab176, https://doi.org/10.1093/noajnl/vdab176
Preclinical and clinical evaluation of German-sourced ONC201 for the treatment of H3K27M-mutant diffuse intrinsic pontine glioma
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab169, https://doi.org/10.1093/noajnl/vdab169
Repeatability of tumor perfusion kinetics from dynamic contrast-enhanced MRI in glioblastoma
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab174, https://doi.org/10.1093/noajnl/vdab174
Involvement of platelet-derived VWF in metastatic growth of melanoma in the brain
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab175, https://doi.org/10.1093/noajnl/vdab175
Quantitative cerebrospinal fluid circulating tumor cells are a potential biomarker of response for proton craniospinal irradiation for leptomeningeal metastasis
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab181, https://doi.org/10.1093/noajnl/vdab181
Clinical Investigations
A validated integrated clinical and molecular glioblastoma long-term survival-predictive nomogram
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdaa146, https://doi.org/10.1093/noajnl/vdaa146
An integrated disease-specific graded prognostic assessment scale for melanoma: contributions of KPS, CITV, number of metastases, and BRAF mutation status
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdaa152, https://doi.org/10.1093/noajnl/vdaa152
Preoperative and early postoperative seizures in patients with glioblastoma—two sides of the same coin?
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdaa158, https://doi.org/10.1093/noajnl/vdaa158
Lack of survival advantage among re-resected elderly glioblastoma patients: a SEER-Medicare study
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdaa159, https://doi.org/10.1093/noajnl/vdaa159
The brain tumor not-for-profit and charity experience of COVID-19: reacting and adjusting to an unprecedented global pandemic in the 21st century
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdaa166, https://doi.org/10.1093/noajnl/vdaa166
The impact of hospital safety-net status on inpatient outcomes for brain tumor craniotomy: a 10-year nationwide analysis
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdaa167, https://doi.org/10.1093/noajnl/vdaa167
Outcome and molecular analysis of young children with choroid plexus carcinoma treated with non-myeloablative therapy: results from the SJYC07 trial
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdaa168, https://doi.org/10.1093/noajnl/vdaa168
An updated histology recode for the analysis of primary malignant and nonmalignant brain and other central nervous system tumors in the Surveillance, Epidemiology, and End Results Program
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdaa175, https://doi.org/10.1093/noajnl/vdaa175
Mebendazole and temozolomide in patients with newly diagnosed high-grade gliomas: results of a phase 1 clinical trial
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdaa154, https://doi.org/10.1093/noajnl/vdaa154
The long-term caregiver burden in World Health Organization grade I and II meningioma: It is not just the patient
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdaa169, https://doi.org/10.1093/noajnl/vdaa169
A case series of pediatric survivors of anaplastic pleomorphic xanthoastrocytoma
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdaa176, https://doi.org/10.1093/noajnl/vdaa176
Incidence and real-world burden of brain metastases from solid tumors and hematologic malignancies in Ontario: a population-based study
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdaa178, https://doi.org/10.1093/noajnl/vdaa178
Phase I trial of intranasal NEO100, highly purified perillyl alcohol, in adult patients with recurrent glioblastoma
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab005, https://doi.org/10.1093/noajnl/vdab005
Phase I dose-escalation, safety, and CNS pharmacokinetic study of dexanabinol in patients with brain cancer
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab006, https://doi.org/10.1093/noajnl/vdab006
Extent of radiological response does not reflect survival in primary central nervous system lymphoma
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab007, https://doi.org/10.1093/noajnl/vdab007
Association of plasma cell-free DNA with survival in patients with IDH wild-type glioblastoma
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab011, https://doi.org/10.1093/noajnl/vdab011
Real-world validity of randomized controlled phase III trials in newly diagnosed glioblastoma: to whom do the results of the trials apply?
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab008, https://doi.org/10.1093/noajnl/vdab008
Multiple positron emission tomography tracers for use in the classification of gliomas according to the 2016 World Health Organization criteria
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdaa172, https://doi.org/10.1093/noajnl/vdaa172
Factors affecting time to brain metastases for stage 2 and 3 breast cancer patients: A large single-institutional analysis with potential screening implications
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab009, https://doi.org/10.1093/noajnl/vdab009
[68Ga]-DOTATATE PET/MRI as an adjunct imaging modality for radiation treatment planning of meningiomas
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab012, https://doi.org/10.1093/noajnl/vdab012
[18F]-FDHT PET/CT as a tool for imaging androgen receptor expression in high-grade glioma
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab019, https://doi.org/10.1093/noajnl/vdab019
A Dutch phase III randomized multicenter trial: whole brain radiotherapy versus stereotactic radiotherapy for 4–10 brain metastases
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab021, https://doi.org/10.1093/noajnl/vdab021
Outcome comparison of patients who develop leptomeningeal disease or distant brain recurrence after brain metastases resection cavity radiosurgery
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab036, https://doi.org/10.1093/noajnl/vdab036
Impact of race on care, readmissions, and survival for patients with glioblastoma: an analysis of the National Cancer Database
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab040, https://doi.org/10.1093/noajnl/vdab040
Temozolomide chronotherapy in patients with glioblastoma: a retrospective single-institute study
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab041, https://doi.org/10.1093/noajnl/vdab041
MRI-based radiomics for prognosis of pediatric diffuse intrinsic pontine glioma: an international study
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab042, https://doi.org/10.1093/noajnl/vdab042
H3K27M and TERT promoter mutations are poor prognostic factors in surgical cases of adult thalamic high-grade glioma
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab038, https://doi.org/10.1093/noajnl/vdab038
Combined 18F-FET PET and diffusion kurtosis MRI in posttreatment glioblastoma: differentiation of true progression from treatment-related changes
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab044, https://doi.org/10.1093/noajnl/vdab044
CovidNeuroOnc: A UK multicenter, prospective cohort study of the impact of the COVID-19 pandemic on the neuro-oncology service
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab014, https://doi.org/10.1093/noajnl/vdab014
Hypermetabolism and impaired cerebrovascular reactivity beyond the standard MRI-identified tumor border indicate diffuse glioma extended tissue infiltration
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab048, https://doi.org/10.1093/noajnl/vdab048
Multiparametric MRI texture analysis in prediction of glioma biomarker status: added value of MR diffusion
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab051, https://doi.org/10.1093/noajnl/vdab051
Timing of glioblastoma surgery and patient outcomes: a multicenter cohort study
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab053, https://doi.org/10.1093/noajnl/vdab053
Bintrafusp alfa (M7824), a bifunctional fusion protein targeting TGF-β and PD-L1: results from a phase I expansion cohort in patients with recurrent glioblastoma
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab058, https://doi.org/10.1093/noajnl/vdab058
Characteristics of diffuse hemispheric gliomas, H3 G34-mutant in adults
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab061, https://doi.org/10.1093/noajnl/vdab061
The role of RB1 alteration and 4q12 amplification in IDH-WT glioblastoma
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab050, https://doi.org/10.1093/noajnl/vdab050
MR spectroscopic imaging predicts early response to anti-angiogenic therapy in recurrent glioblastoma
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab060, https://doi.org/10.1093/noajnl/vdab060
An integrative analysis of genome-wide 5-hydroxymethylcytosines in circulating cell-free DNA detects noninvasive diagnostic markers for gliomas
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab049, https://doi.org/10.1093/noajnl/vdab049
Accelerator-based BNCT for patients with recurrent glioblastoma: a multicenter phase II study
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab067, https://doi.org/10.1093/noajnl/vdab067
Radiological assessment schedule for 1p/19q-codeleted gliomas during the surveillance period using parametric modeling
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab069, https://doi.org/10.1093/noajnl/vdab069
Plasma IL-8 and ICOSLG as prognostic biomarkers in glioblastoma
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab072, https://doi.org/10.1093/noajnl/vdab072
Phase II trial of proton therapy versus photon IMRT for GBM: secondary analysis comparison of progression-free survival between RANO versus clinical assessment
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab073, https://doi.org/10.1093/noajnl/vdab073
Salvage therapies for radiation-relapsed isocitrate dehydrogenase-mutant astrocytoma and 1p/19q codeleted oligodendroglioma
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab081, https://doi.org/10.1093/noajnl/vdab081
Incidence, risk factors, and prognosis of meningiomas with distant metastases at presentation
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab084, https://doi.org/10.1093/noajnl/vdab084
Outcomes following upfront radiation versus monitoring in atypical meningiomas: 16-year experience at a tertiary medical center
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab094, https://doi.org/10.1093/noajnl/vdab094
Predictors of survival in elderly patients undergoing surgery for glioblastoma
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab083, https://doi.org/10.1093/noajnl/vdab083
Necessity for craniospinal irradiation of germinoma with positive cytology without spinal lesion on MR imaging—A controversy
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab086, https://doi.org/10.1093/noajnl/vdab086
A phase Ib/IIa trial of 9 repurposed drugs combined with temozolomide for the treatment of recurrent glioblastoma: CUSP9v3
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab075, https://doi.org/10.1093/noajnl/vdab075
MYD88 L265P mutation in primary central nervous system lymphoma is associated with better survival: A single-center experience
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab090, https://doi.org/10.1093/noajnl/vdab090
Clinical characterization of adult medulloblastoma and the effect of first-line therapies on outcome; The MD Anderson Cancer Center experience
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab079, https://doi.org/10.1093/noajnl/vdab079
Validation of diffusion MRI as a biomarker for efficacy using randomized phase III trial of bevacizumab with or without VB-111 in recurrent glioblastoma
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab082, https://doi.org/10.1093/noajnl/vdab082
Analysis of morphological characteristics of IDH-mutant/wildtype brain tumors using whole-lesion phenotype analysis
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab088, https://doi.org/10.1093/noajnl/vdab088
Low tumor cell content predicts favorable prognosis in germinoma patients
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab110, https://doi.org/10.1093/noajnl/vdab110
Avelumab in newly diagnosed glioblastoma
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab118, https://doi.org/10.1093/noajnl/vdab118
Treatment barriers and clinical outcome of children with medulloblastoma in China: a report from the Chinese Children’s Cancer Group (CCCG)
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab134, https://doi.org/10.1093/noajnl/vdab134
Fifteen-year trends and differences in mortality rates across sex, age, and race/ethnicity in patients with brainstem tumors
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab137, https://doi.org/10.1093/noajnl/vdab137
Results of a phase I trial to assess the safety of macitentan in combination with temozolomide for the treatment of recurrent glioblastoma
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab141, https://doi.org/10.1093/noajnl/vdab141
Phase II trial of natalizumab for the treatment of anti-Hu associated paraneoplastic neurological syndromes
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab145, https://doi.org/10.1093/noajnl/vdab145
Multimodal therapy of cavernous sinus meningioma: Impact of surgery and 68Ga-DOTATATE PET-guided radiation therapy on tumor control and functional outcome
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab114, https://doi.org/10.1093/noajnl/vdab114
Marizomib alone or in combination with bevacizumab in patients with recurrent glioblastoma: Phase I/II clinical trial data
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab142, https://doi.org/10.1093/noajnl/vdab142
Pharmacoresistant seizures and IDH mutation in low-grade gliomas
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab146, https://doi.org/10.1093/noajnl/vdab146
Intraoperative DNA methylation classification of brain tumors impacts neurosurgical strategy
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab149, https://doi.org/10.1093/noajnl/vdab149
Association between height and the risk of primary brain malignancy in adults: a nationwide population-based cohort study
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab098, https://doi.org/10.1093/noajnl/vdab098
Impact of lymphopenia on survival for elderly patients with glioblastoma: A secondary analysis of the CCTG CE.6 (EORTC 26062-22061, TROG08.02) randomized clinical trial
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab153, https://doi.org/10.1093/noajnl/vdab153
A randomized phase II trial of efficacy and safety of the immunotherapy ALECSAT as an adjunct to radiotherapy and temozolomide for newly diagnosed glioblastoma
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab156, https://doi.org/10.1093/noajnl/vdab156
Changes of healthy brain tissue after salvage radiotherapy of glioblastoma
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab139, https://doi.org/10.1093/noajnl/vdab139
Multiparametric radiomic tissue signature and machine learning for distinguishing radiation necrosis from tumor progression after stereotactic radiosurgery
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab150, https://doi.org/10.1093/noajnl/vdab150
Immunotherapeutic early-phase clinical trials and malignant gliomas: A single-center experience and comprehensive immunophenotyping of circulating leukocytes
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab160, https://doi.org/10.1093/noajnl/vdab160
Reevaluating surgery and re-irradiation for locally recurrent pediatric ependymoma—a multi-institutional study
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab158, https://doi.org/10.1093/noajnl/vdab158
A phase II study of laser interstitial thermal therapy combined with doxorubicin in patients with recurrent glioblastoma
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab164, https://doi.org/10.1093/noajnl/vdab164
Determinants of impairments in functioning, fatigue, and participation ability in pediatric brain tumor survivors
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab161, https://doi.org/10.1093/noajnl/vdab161
Extent of MGMT promoter methylation modifies the effect of temozolomide on overall survival in patients with glioblastoma: a regional cohort study
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab171, https://doi.org/10.1093/noajnl/vdab171
Phase I study using crenolanib to target PDGFR kinase in children and young adults with newly diagnosed DIPG or recurrent high-grade glioma, including DIPG
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab179, https://doi.org/10.1093/noajnl/vdab179
Reviews
Clinical correlates for immune checkpoint therapy: significance for CNS malignancies
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdaa161, https://doi.org/10.1093/noajnl/vdaa161
Adult precision medicine: learning from the past to enhance the future
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdaa145, https://doi.org/10.1093/noajnl/vdaa145
Inefficiencies in phase II to phase III transition impeding successful drug development in glioblastoma
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdaa171, https://doi.org/10.1093/noajnl/vdaa171
New developments in neurofibromatosis type 2 and vestibular schwannoma
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdaa153, https://doi.org/10.1093/noajnl/vdaa153
The promise of DNA damage response inhibitors for the treatment of glioblastoma
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab015, https://doi.org/10.1093/noajnl/vdab015
Newly discovered neuron-to-glioma communication: new noninvasive therapeutic opportunities on the horizon?
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab018, https://doi.org/10.1093/noajnl/vdab018
Therapeutic cancer vaccines for pediatric malignancies: advances, challenges, and emerging technologies
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab027, https://doi.org/10.1093/noajnl/vdab027
Systematic review and meta-analysis of breast cancer brain metastasis and primary tumor receptor expression discordance
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab010, https://doi.org/10.1093/noajnl/vdab010
Adhesion G protein-coupled receptors in glioblastoma
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab046, https://doi.org/10.1093/noajnl/vdab046
Lessons learned from contemporary glioblastoma randomized clinical trials through systematic review and network meta-analysis: part 1 newly diagnosed disease
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab028, https://doi.org/10.1093/noajnl/vdab028
Lessons learned from contemporary glioblastoma randomized clinical trials through systematic review and network meta-analysis: part 2 recurrent glioblastoma
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab029, https://doi.org/10.1093/noajnl/vdab029
Systematic review and network meta-analysis of the efficacy of existing treatments for patients with recurrent glioblastoma
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab052, https://doi.org/10.1093/noajnl/vdab052
Anti-PD-1 checkpoint blockade monotherapy in the orthotopic GL261 glioma model: the devil is in the detail
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab066, https://doi.org/10.1093/noajnl/vdab066
Health-related quality of life in meningioma
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab089, https://doi.org/10.1093/noajnl/vdab089
Classification of true progression after radiotherapy of brain metastasis on MRI using artificial intelligence: a systematic review and meta-analysis
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab080, https://doi.org/10.1093/noajnl/vdab080
A systematic review of the utility of amino acid PET in assessing treatment response to bevacizumab in recurrent high-grade glioma
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab003, https://doi.org/10.1093/noajnl/vdab003
Mouse models of glioblastoma for the evaluation of novel therapeutic strategies
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab100, https://doi.org/10.1093/noajnl/vdab100
Systematic review—Time to malignant transformation in low-grade gliomas: Predicting a catastrophic event with clinical, neuroimaging, and molecular markers
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab101, https://doi.org/10.1093/noajnl/vdab101
Glioblastoma as an age-related neurological disorder in adults
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab125, https://doi.org/10.1093/noajnl/vdab125
Receptor tyrosine kinases as druggable targets in glioblastoma: Do signaling pathways matter?
Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab133, https://doi.org/10.1093/noajnl/vdab133
